Mesoblast Limited (MESO) gave investors a pleasant surprise today, securing the FDA panel's overwhelming recommendation for its lead asset Ryoncil, proposed for pediatric steroid-refractory acute graft versus host disease. Not many would have expected Ryoncil to garner the advisory committee's positive vote after the release of the FDA briefing documents on August 10.
from RTT - Biotech https://ift.tt/3apHDyn
via IFTTT
No comments:
Post a Comment